{"groups":[{"description":"* MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.\n* Participants will undergo DCE and DSC-MRI imaging at the following time points:\n\n  * no more than 3 weeks prior to MLA (OPTIONAL)\n  * within approximately 4 days after MLA\n  * 2-4 weeks after MLA\n  * Every 12 weeks (+/- 7 days) for the first year or until disease progression","id":"FG000","title":"Arm A (MRI-guided Laser Ablation)"},{"description":"* MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.\n* Within 7 days of MLA (range 2-14 days) doxorubicin will be given intravenously on an outpatient basis weekly for 6 weeks at a dose of 25 mg/m\\^2 over 5-30 minutes\n* Following the completion of doxorubin, etoposide 50 mg/m\\^2/day will be given orally for 21 days of each 28-day cycle (treatment can continue up to 24 cycles)\n* Participants will undergo DCE and DSC-MRI imaging at the following time points:\n\n  * no more than 3 weeks prior to MLA (OPTIONAL)\n  * within approximately 4 days after MLA\n  * 2-4 weeks after MLA\n  * every 8 weeks (+/- 7 days) until 2 years have elapsed or disease progression, whichever comes first","id":"FG001","title":"Arm B (MRI-guided Laser Ablation, Doxorubicin, Etoposide)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Disease progression"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"1"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}